2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.133 Kate Lovett NACLC23 abstract

PP01.133 Kate Lovett NACLC23 abstract

Pdf Summary

A study was conducted to evaluate the clinical and economic outcomes associated with different genomic testing strategies in advanced non-small cell lung cancer (aNSCLC). The study utilized two databases, the Flatiron Health aNSCLC database and the IQVIA PharMetrics Plus healthcare claims database. The first part of the study assessed the association between testing strategies and overall survival (OS), while the second part explored the economic outcomes. <br /><br />The results showed that upfront next-generation sequencing (NGS) genomic testing had the longest median OS (20.9 months) compared to upfront non-NGS genomic testing (17.5 months), NGS testing after 1L therapy (18.2 months), and no NGS testing (16.9 months). The OS benefit was largely attributed to the initiation of targeted therapy in the first-line treatment. <br /><br />In terms of healthcare costs, patients with upfront NGS testing had similar costs compared to those with upfront non-NGS testing and NGS testing after 1L therapy. All-cause and NSCLC-related costs were lowest in patients with no NGS testing. <br /><br />Based on these findings, the study concluded that upfront NGS testing resulted in longer OS in aNSCLC, likely due to earlier initiation of appropriate treatment. However, healthcare costs were comparable among the different testing strategies. <br /><br />In summary, this real-world study demonstrates the importance of genomic testing in aNSCLC and its impact on clinical outcomes. It also highlights the need to consider the economic implications of different testing strategies.

Keywords

genomic testing

advanced non-small cell lung cancer

aNSCLC

Flatiron Health

IQVIA PharMetrics Plus

overall survival

next-generation sequencing

targeted therapy

healthcare costs

clinical outcomes